Antibody discovery and engineering
Harness the power of our advanced antibody discovery platforms to accelerate your therapeutic development. From cancer to autoimmune disorders, we're here to transform your targets into ground-breaking treatments.
Elevate your late-stage development with advanced antibody solutions
Antibody discovery is a sophisticated process that employs advanced methodologies to identify and develop antibodies with specific binding affinities to target antigens. Successful campaigns lead to therapeutics for various diseases, including cancer, autoimmune disorders and infections, advancing personalized medicine and treatment efficacy. This process is equally effective in generating highly specific reagent antibodies for research purposes.
Why partner with Enzene?
We are a global Continuously Innovative Development and Manufacturing Organization (CIDMO), dedicated to changing the paradigm by which affordable biologic and biosimilar medicines are brought to market. Since Enzene’s inception, our innovative agility has enabled us to continually introduce transformative processes in biologics manufacturing that significantly increase product yields of complex biologics and monoclonal antibodies (mAbs) while reducing the manufacturing footprint and the cost of production.
Game-changing innovation is only the beginning, though. We are Enzene, and that means that our values of innovation, entrepreneurship, respect, candor, excellence, and integrity underscore everything we do from project management and communications to teamwork and ideation. To us, true partnership is about driving biotech innovation while doing so in a way that develops long-lasting trusted partnerships.
Understanding our antibody discovery and engineering approach
1 Multi-pronged approach to lead candidate generation
Enzene employs a diverse strategy for antibody discovery, combining:
- Conventional hybridoma technology
- Patient-derived B-cell libraries
- AI/ML-generated synthetic libraries
- Display engineering
Libraries generated through these processes undergo rigorous selection to isolate sequences with the highest specificity and affinity for the target. AI/ML tools integrated at various screening stages accelerate lead candidate identification, enhancing efficiency and speed. After identification, antibodies are characterized through affinity maturation and epitope mapping to optimize binding and functionality. Advanced methods like X-ray crystallography or cryo-EM are used to elucidate antibody-antigen interactions at the atomic level.
2 Display engineering for sequence optimization
axzxczxc
Display engineering fine-tunes discovered antibody candidates to match desirable properties or “design goals,” improving drug characteristics such as target binding affinity, functionality and cross-species reactivity. Two key techniques in this field are phage display and yeast display, both of which excel in antibody engineering and sequence optimization:
Phage display:
- Displays antibody fragments on bacteriophage surfaces
- Screens large libraries (up to 10^9 variants)
- Enables rapid identification of high-affinity antibodies
- Facilitates affinity maturation and sequence optimization
Yeast display
- Expresses full-length antibodies or fragments on yeast cell surfaces
- Provides native post-translational modifications
- Suitable for complex selections requiring mammalian protein folding
- Used for affinity maturation and sequence optimization
3 Lead candidate identification: Screening
This critical stage involves systematic evaluation of promising candidates using:
- High-throughput screening technologies
- Validation assays (in vitro and in vivo testing)
- Advanced analytical techniques (mass spectrometry, surface plasmon resonance, functional assays)
Screening assays are utilized at multiple steps throughout the antibody discovery workflow to ensure the selection of the most promising candidates.
4 Lead candidate evaluation
This step ensures that candidates possess desirable drug-like properties before advancing to preclinical and clinical development. The evaluation focuses on:
- Activity and efficacy
- Safety profile
- Pharmacokinetics (PK)
- Pharmacodynamics (PD)
5 Continuum to pre-clinical and clinical development
This critical stage involves systematic evaluation of promising candidates using:
- High-throughput screening technologies
- Validation assays (in vitro and in vivo testing)
- Advanced analytical techniques (mass spectrometry, surface plasmon resonance, functional assays)
Screening assays are utilized at multiple steps throughout the antibody discovery workflow to ensure the selection of the most promising candidates.
